D-2-HG INHIBITION SHOWS PROMISE IN ASTROCYTOMAMarch 6, 2021
In a study funded by the National Institutes of Health (NIH), researchers tested a novel combination treatment approach on mice with tumours with characteristics similar to human astrocytomas — a type of slow-growing glioma—and found tumour regression in 60 percent of the mice treated. These encouraging results, published in the Journal of Clinical Investigation, could be the first step toward developing a treatment for this type of brain cancer.
Led by senior authors Maria Castro, Ph D and Pedro Lowenstein, MD, Ph D along with a team of researchers at the University of Michigan Rogel Cancer Center in Ann Arbor specifically tested inhibitors of the compound D-2-Hydroxyglutarate (D-2-HG), which is produced by cancer cells, on a mouse version of astrocytoma carrying mutations in the genes IDH1 and ATRX, along with an inactivated form of the tumour suppressor protein 53 (TP53) gene.
When the implanted mice were treated with a drug to block the production of D-2-HG along with the standard of care radiation and temozolomide treatments, their survival significantly improved. Looking more closely at tumour cells grown in dishes, the researchers saw that blocking D-2-HG caused the cells to become more susceptible to radiation treatment. However, the treatment
also increased the amount of an “immune checkpoint” protein, which tumours use to turn off T cells and evade the immune system.
Inhibiting this immune checkpoint protein with an additional drug resulted in an even greater improvement in survival, because the mouse’s own immune system was able to attack the tumour. Importantly, this combination therapy also led to immunological memory against the glioma, meaning that the mouse now had T cells tailored to the specific tumour. Because gliomas almost always grow back after treatment, these T cells make the animal better prepared to fend off regrowth.
It must be emphasised that these experiments were performed in mice. Nonetheless the preclinical results produced by this combination therapy could represent a key advance in developing an improved treatment regimen, which combines D-2-HG and immune checkpoint inhibition, radiation, and temozolomide, for patients with astrocytomas.